Janssen publishes positive safety and efficacy data for single-dose COVID-19 vaccine
Janssen has published positive data from the Phase 3 studies of its single-dose COVID-19 vaccine candidate, showing it to be 66% effective overall in preventing coronavirus in participants.
Published
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date
